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Abstract: A macrocyclic alkaloid, halicyclamine A, was re-discovered from an Indonesian 
marine sponge of Haliclona sp. 05A08 as an anti-dormant mycobacterial substance. To 
clarify action-mechanism of halicyclamine A, halicyclamine A-resistant strains were 
screened from the transformants of Mycobacterium smegmatis  with the genomic DNA 
library of M.  bovis  BCG, which were constructed in the multi-copy shuttle cosmid 
pYUB145. Sequencing analysis of the cosmids isolated from the halicyclamine A-resistant 
transformants revealed that the responsible gene was involved in the genome region 
between 2920.549 kb and 2933.210 kb. Further experiments using the transformants   
over-expressing individual gene contained in the responsible region were executed, and the 
transformant, which over-expressed  BCG2664  gene assigned as dedA  gene,  was found 
to become halicyclamine A-resistant.  This evidence strongly suggested that DedA 
protein correlates with the action-mechanism of halicyclamine A as an anti-dormant 
mycobacterial substance. 
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1. Introduction  
Tuberculosis (TB) is one of the most common causes of morbidity and mortality in HIV-positive 
adults living in poverty [1]. Eight million new TB cases and two million deaths from TB are estimated 
each year [2]. It is now generally accepted that the requirement for a minimum six months treatment 
for TB is due to the difficulty in eradicating non-replicating persistent Mycobacterium tuberculosis. 
Therefore,  new  lead  compounds,  which  are  effective  against  M.  tuberculosis  in  both  active  and 
dormant states, are urgently needed. Although physiology of latent M. tuberculosis infection is still 
unclear, hypoxic condition was found to induce dormant state of Mycobacterium sp., which has a drug 
susceptibility profile resembling that of the latent M. tuberculosis infection
 [3–5]. Recently, we have 
established  a  screening  system  searching  for  anti-dormant  mycobacterial  substances  [6–8].  In  this 
assay  system,  M.  tuberculosis  H37Ra  under  hypoxic  conditions,  became  highly  resistant  against 
isoniazid,  which  is  one  of  the  first-line  drugs  for  TB.  Thus,  the  MIC  value  of  isoniazid  against 
M. tuberculosis H37Ra was 0.05 µg/mL under standard aerobic growth condition. While, the MIC 
value of isoniazid was more than 100 µg/mL under nitrogen atmosphere containing 0.2% oxygen. In 
the course of our search for anti-dormant mycobacterial substances from marine organisms by using 
this assay system, a macrocyclic alkaloid, halicyclamine A (Figure 1), has been re-discovered as an  
anti-dormant Mycobacterial substance from an Indonesian marine sponge of Haliclona sp 05A08 [6]. 
Halicyclamine A showed potent anti-microbial activity against M. smegmatis (MIC = 2.5 µg/mL), 
M. bovis BCG (MIC = 1.0 µg/mL), and M. tuberculosis H37Ra (MIC = 5.0 µg/mL) under standard 
aerobic growth condition as well as dormancy-inducing hypoxic condition [6]. On the other hand, 
M. Jaspars, et al. reported that the crude spongean extract containing halicyclamine A showed an 
inhibitory activity against human inosine 5’-monophosphate dehydrogenase (IMPDH) [9]. In order to 
clarify  action-mechanism  of  halicyclamine  A,  we  previously  prepared  the  transformants  of  
M. smegmatis, which over-expressed mycobacterial IMPDHs, since the transformant over-expressing 
target proteins often confer drug-resistance [10,11]. However, the IMPDH  over-expressing  strains 
showed the same MIC value against halicyclamine A with that of the wild-type M. smegmatis [6]. In 
this paper, our continued study of the action-mechanism of halicyclamine A is presented.  
2. Results and Discussion  
2.1. Isolation of the Halicyclamine A-Resistant Clones from the Transformants of M. smegmatis with 
Genomic DNA Library 
To identify the gene that could confer a resistance to halicyclamine A, we prepared transformants of 
Mycobacterium smegmatis, which were transformed with the genomic DNA library of M. bovis BCG 
constructed in the multi-copy shuttle cosmid pYUB145. Then, halicyclamine A-resistant clones were 
screened from over the 4,000 transformants by the dish culture containing 5.0 µg/mL (2 × MIC value 
for M. smegmatis) of halicyclamine A. We could isolate two transformants, designated ICHO2004 and 
ICHO2005, as the resistant strains to halicyclamine A (Figure 2). Each resistant strain was cultured in 
the Middlebrook 7H9 broth containing hygromycin B, and the two cosmids (pYUB145_2004 and 
pYUB145_2005) were extracted from the ICHO2004 strain and ICHO2005 strain, respectively. Then, 
the pYUB145_2004 and pYUB145_2005 cosmids were found to contain 23.070 kb (coordinates from Mar. Drugs 2011, 9                          
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2920.549 kb to 2943.619 kb) and 26.587 kb (coordinates from 2906.623 kb to 2933.210 kb) genome 
fragments, respectively. This data indicated that the gene for giving resistnace to halicyclamine A 
would  be  contained  in  the  genome  region  of  M.  bovis  BCG  from  2920.549  kb  to  2933.210  kb  
(12.661 kb) (Figure 3). 
Figure 1. Chemical structure of halicyclamine A. 
 
Figure 2. Halicyclamine A resistant-strains of M. smegmatis transformed with genomic 
DNA  library.  The  wild-type  strain  and  transformants  (ICHO2004  and  ICHO2005)  of  
M. smegmatis were cultured in 7H9 broth, and the concentration of the each culture was 
adjusted to 1 × 10
5 CFU/mL. The 10 µL aliquot of each culture was spread on a 7H10 agar 
plate in the presence or absence of halicyclamine A (5.0 µg/mL). 
 
Figure  3.  Gene  maps  of  the  cosmids  extracted  from  the  halicyclamine  A-resistant 
transformants. 
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2.2.  Second  Selection  of  the  Transformants  of  M. smegmatis  Expressing  the  Candidate  Region 
Showing Resistance to Halicyclamine A 
To narrow down candidate genes expressing resistance to halicyclamine A, we then divided the 
12.661 kb common region into six areas  (S1-S6) as shown in Figure 4a and established six 
transformants (ICHO1007-ICHO1012) of M. smegmatis, which over-expressed each area. As shown in 
Figure 4b, all established transformants showed resistance against hygromycin B or kanamycin, which 
corresponds  to the antibiotic-resistance  genes in the plasmids of pMV206 or pMV261.  The 
transformant of ICHO1010, which over-expressed the S4 area containing BCG2662,  BCG2663, 
BCG2664 and BCG2665 genes, showed resistance against 5.0 µg/mL concentartion of halicyclamine 
A, whereas no resistance to halicyclamine A was observed in both wild-type and other transformants 
of M. smegmatis. 
Figure 4. Growth of the transformants of M. smegmatis over-expressing candidate area 
showing resistance to halicyclamine A on the 7H10 agar plate containing halicyclamine A. 
(a) Gene map of the cloning area to prepare transformants of M. smegmatis. (b) Each strain 
(wild-type of M. smegmatis, ICHO1007, ICHO1008, ICHO1009, ICHO1010, ICHO1011 
and ICHO1012) was cultured in the 7H9 broth, and then the cultures were adjusted to  
1 × 10
5 CFU/mL. The 10 µL aliquots of each culture were spread on the 7H10 agar plates 
in the presence or absence of halicyclamine A (5.0 µg/mL). 
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2.3. Identification of the Gene Causing Resistance to Halicyclamine A 
To identify the gene causing resistance to halicyclamine A, four transformants   
(ICHO1013-ICHO1016) of M. smegmatis, which over-expressed each BCG2662, BCG2663, BCG2664 
and BCG2665 gene, were prepared, and we observed growth of the four transformants on the 7H10 
agar containing 5 µg/mL concentration of halicyclamine A. As a result, the only ICHO1015 strain, 
which over-expresses BCG2664 gene assigned as dedA gene, showed resistance to halicyclamine A  
(Figure 5). In addition, the MIC value of halicyclamine A against ICHO1015 strain was evaluated  
5.0 µg/mL by agar dilution assay using 7H10 agar plate, whereas 2.5 µg/mL of halicyclamine A 
inhibited the growth of the wild type of M. smegmatis completely (data not shown) [12]. Although 
further study is necessary for the identification of the target molecule of halicyclamine A, these results 
strongly suggested that DedA protein correlates with the action mechanism of halicyclamine A as an 
anti-dormant mycobacterial substance.  
Figure  5.  Growth of the transformants of M. smegmatis over-expressing the candidate 
gene  for  giving  resistance  to  halicyclamine  A  on  the  7H10  agar  plate  containing 
halicyclamine  A.  Each strain (wild-type  of  M.  smegmatis,  ICHO1013,  ICHO1014, 
ICHO1015 and ICHO1016) was cultured in the 7H9 broth, and then the cultures were 
adjusted to 1 × 10
5 CFU/mL. The 10 µL aliquots of each culture were spread on the 7H10 
agar plate in the presence or absence of halicyclamine A (5.0 µg/mL). 
 
DedA family gene exists in most bacterial genome and is speculated to encode integral membrane 
protein with completely unknown functions. M. smegmatis, M. bovis BCG and M. tuberculosis H37Rv 
have seven genes of dedA family in their genome, respectively. The homology between BCG2664 
gene and one of dedA genes in M. tuberculosis H37Rv is 100%, while the homology with that in 
M.smegmatis is 38%. Although no precise function of DedA family protein has been reported, several 
studies suggested that DedA family protein might function as envelope biogenesis and maintenance. 
For instance, a DedA protein in Ralstonia metallidurans was shown to be required for resistance to 
selenite and was thought to be involved in transport function [13]. The yghB and yqjA genes, which Mar. Drugs 2011, 9                          
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belong  to  the  dedA  gene  family,  play redundant and critical roles in membrane biology that are 
essential for completion of cell division in E. coli [14]. From these observations, halicyclamine A 
possibly inhibits the function of envelope biogenesis and maintenance in Mycobacterium species by 
inhibition of DedA protein. 
3. Experimental Section  
3.1. Materials 
Middlebrook  7H9  broth,  Middlebrook  7H10  agar,  Middlebrook  OADC  Enrichment,  and  
Luria-Bertani  (LB)  broth  were  obtained  from  BD  (Franklin  Lakes,  NJ, USA).  DNA  restriction 
enzymes and T4 DNA ligase were obtained from New England BioLabs INC. (Ipswich, MA, USA). 
Expand High Fidelity PCR System (Roche Applied Science, Mannheim, Germany) was used for PCR. 
Carbenicillin, hygromycin B, isoniazid, kanamycin and other chemicals were purchased from Sigma 
(St. Louis, MO, USA). Halicyclamine A was isolated from Indonesian marine sponge of Haliclona sp. 
05A08 (Figure 1). Briefly, the methanol extract (43 g) of the dry sponge (200 g) were partitioned by 
the alkaloid extraction procedure. The alkaloid fraction (2.5 g) was subjected to silica gel column 
chromatography (eluted with CHCl3-MeOH containing 1.0% triethylamine) and HPLC [COSMOSIL 
Sugar-D  column  (Nacalai  tesque,  Kyoto,  Japan);  eluted  with  CHCl3-CH3CN-H2O]  to  isolate 
halicyclamine  A  (20%  yield  from  the  alkaloid  fraction).  Halicyclamine  A  was  identified  by  
ESI-TOF-MS and 2D-NMR analyses and comparison with authentic spectral data [9,15]. 
3.2. Bacterial Culture 
Mycobacterium strains were grown in Middlebrook 7H9 broth containing 10% Middlebrook OADC 
enrichment,  0.2%  glycerol,  and  0.05%  Tween  80,  or  on  Middlebrook  7H10  agar  containing  10% 
Middlebrook OADC enrichment and 0.5% glycerol. Escherichia coli DH5α was used for cloning and 
maintaining plasmid and grown in Luria-Bertani (LB) liquid medium. E. coli HB101 was used for 
construction of the genomic DNA library of M. bovis BCG and grown in LB liquid medium containing 
0.3%  maltose  and  10  mM  MgSO4.  The  concentrations  of  antibiotics  used  were  100  µg/mL 
(carbenicillin),  150  µg/mL  (hygromycin  B),  and  40  µg/mL  (kanamycin)  for  E.  coli  strains  and  
50 µg/mL (hygromycin B) and 20 µg/mL (kanamycin) for Mycobacterium strains, respectively. 
3.3. Construction of Gnomic DNA Library and Transformation of M. smegmatis mc
2155 
The  chromosomal  DNA  of  M.  bovis  BCG  Pasteur  was  prepared  by  the 
hexadecyltrimethylammonium  bromide  (CTAB)  method  [16].  The  chromosomal  DNA  was  then 
digested  with  restriction  endonuclase  Sau3AI  to  produce  approximately  30  kb  DNA  fragments. 
Genomic DNA library was constructed in the E. coli-Mycobacterium shuttle cosmid, pYUB145, by 
using the double cos vector strategy as previously described [17]. Briefly, the left and right arms of 
pYUB145  were  generated  by  digestion  with  restriction  endonuclases  of  XbaΙ  and  BamHΙ.  The 
fragments of genome were ligated to the both arms of pYUB145. The mixture of ligations were in 
vitro  packaged  with  packaging  mix  of  MaxPlax  Lambda  Packaging (Epicentre),  and  the  resulting 
recombinant cosmids were transduced to E. coli HB101. The transformants of E. coli HB101 were Mar. Drugs 2011, 9                          
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selected on the LB agar plates containing carbenicillin. Over 3 × 10
5 independent clones were pooled, 
and cosmids for transformation of M. smegmatis was obtained by large scale DNA preparation using a 
standard alkaline lysis method. In order to prepare transformants of M. smegmatis with genomic DNA 
library,  M.  smegmatis  mc
2155  were  grown  at  37  °C  as  described  above  until  the  optical  density 
reached 0.8–1.0 at 600 nm. The cultures were centrifuged, and the resulting pellets were washed with 
10% glycerol twice and re-suspended in the same solution (1/10th of the initial culture volume). The 
cell suspensions were mixed with gnomic DNA library and electroporated (2500 V, 25 µF, 1000 Ω). 
The resulting suspensions were incubated at 37 °C for 4 h and then plated on Middlebrook 7H10 agar 
containing 50 µg/mL of hygromycin B. 
3.4.  Isolation of Halicyclamine A-Resistant Clones from the Transformants of M. smegmatis with 
Genomic DNA Library and End Sequencing of Cosmids 
Halicyclamine  A-resistant  clones  were  screened  from  over  the  4  ×  10
3  transformants  of  M. 
smegmatis with the genomic DNA library by cultivating on the 7H10 agar containing 5.0 µg/mL 
concentration of halicyclamine A. Then, the resistant clones against halicyclamine A were grown in 
the 7H9 broth containing hygromycin B, and cosmids for end sequencing were isolated by using 
standard  alkaline  lysis  method.  The  cosmids  extracted  from  the  halicyclamine  A-resistant 
transformants  were  subjected  to  end  sequencing  (MACROGEN,  South  Korea).  The  primers  P1  
(5’-GTACGCCACCGCCTGGTTC-3’)  and  P2  (5'-GTGCCACCTGACGTCTAAG-3’),  which were 
designed based on the sequence of cosmid vector pYUB415, were used to amplify the integrated end 
sequences of the cosmids. The obtained sequences were analyzed by BLAST search using the database 
of BCGList (http://genolist.pasteur.fr/BCGList/) and Comprehensive Microbial Resource in J. Craig 
Venter Institute (http://cmr.tigr.org/cgi-bin/CMR/CmrHomePage.cgi). 
3.5. Preparation of the Transformants of M. smegmatis Over-Expressing the Candidate-Genes for 
Giving Resistance to Halicyclamine A 
The gene regions or genes for candidate giving resistance to halicyclamine A were PCR amplified 
from the cosmids pYUB415_2004 or pYUB415_2005 by using the primer pairs as shown in Table 1. 
PCR was performed using a program of 30 cycles of 94 °C for 15 sec, 57 °C for 30 sec and 68 °C for  
1  min/kb.  Following  cloning  into  pCR2.1-TOPO  (Invitrogen)  and  sequencing,  the  cloned  PCR 
fragment was excised using the primer-introduced restriction sites and cloned into the mycobacterial 
expression vector pMV261 having hsp60 promoter and kanamycin-resistant gene or promoter-less 
shuttle vector pMV206 having hygromycin B-resistant gene. Description of plasmids and name of 
transformants were listed as shown in Table 1. The transformation of M. smegmatis was performed by 
above mentioned method. Mar. Drugs 2011, 9                          
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Table 1. List of the transformants of M. smegmatis and description of plasmids. 
Strains  Plasmids  Description of plasmids  Sequence of primers (5’ to 3’) 
F; Forward primer, R; Reverse primer 
ICHO1007  pMV206  Cloned S1 area
# (2919991- 2923343 bp 
of M. bovis BCG genome)* 
F:TCTAGAGCCACACCCTGATAGCATTG 
R: AAGCTTTCGCGACGGCTGGAATG 
ICHO1008  pMV206  Cloned S2 area
 # (2924490–2923316 bp 
of M. bovis BCG genome)* 
F:GGATCCAACTGTTTCCGCACGAGGAG 
R:CTGCAGTCAACGGCGAACATTCCAGC 
ICHO1009  pMV261  Cloned S3 area
 # (2926966–2924589 bp 
of M. bovis BCG genome)* 
F:GGATCCATCCAGGAGGTCGCAGATGTC 
R: GAATTCGTGATGTTCGCGCCTAACGG 
ICHO1010  pMV206  Cloned S4 area
 # (2926766–2929363 bp 
of M. bovis BCG genome)* 
F:CAGCTGATAGCTCTGCGCGTACGAC 
R: TTCGAAGATCAGCAACGGGCTGGAC 
ICHO1011  pMV206  Cloned S5 area
 # (2929454–2931112 bp 
of M. bovis BCG genome)* 
F: GGATCCTGCGGTATCGCTTGCCTTG 
R: AAGCTTGCGCGACTACGCAGCTC 
ICHO1012  pMV206  Cloned S6 area
 # (2930898–2933532 bp 
of M. bovis BCG genome)* 
F:GGATCCAAGCGGCTAACTGTAGGCCTG 
R: AAGCTTTCAGCCCGGTGGTGTTGG 
ICHO1013  pMV261  Cloned BCG2662 gene (2926980–
2927222 bp of M. bovis BCGgenome)* 
F:GAATTCAGGACAACCCGCATGGTCG 
R: AAGCTTTATCACTCAGCGCCGGTACG 
ICHO1014  pMV261  Cloned BCG2663 gene (2927223–
2927900 bp of M. bovis BCG genome)* 
F: GAATTCCCGGTCAGGCATTCTTTACCC 
R:AAGCTTGAAAGTTCCAGTTGCGCACGAC 
ICHO1015  pMV261  Cloned BCG2664 gene(2928096–
2928752 bp of M. bovis BCG genome)* 
F: GAATTCCCGGTCAGGCATTCTTTACCC 
R: AAGCTTCAAGCCGGTCGGTCACG 
ICHO1016  pMV261  Cloned BCG2665 gene(2928915–
2929361 bp of M. bovis BCG genome)* 
F: GGATCCATGCACCATGGGCCTGATCAC 
R: GAATTCTACGGCCGGGATCAGCAAC 
#; Name of area corresponds to the Figure 4a. *; Coordinate of M. bovis BCG genome is based on the database of 
BCGList (http://genolist.pasteur.fr/BCGList/). 
4. Conclusions  
We previously found that a marine spongian macrocyclic alkaloid, halicyclamine A, showed potent 
anti-mycobacterial activity under standard aerobic growth conditions as well as dormancy-inducing 
hypoxic condition, although its action-mechanism was not clear. In this paper, we searched the gene, 
which gives a resistance to halicyclamine A, using the genomic DNA library of M. bovis BCG, since 
the transformants over-expressing target proteins often confer drug-resistance.
 Then, we finally found 
that  a  transformant  of  M.  smegmatis,  which  over-expressed  BCG2664  gene  coded  DedA  protein, 
showed  the  resistance  to  halicyclamine  A.  This evidence strongly suggested that DedA protein 
correlates with the action-mechanism of halicyclamine A as an anti-dormant Mycobacterial substance. 
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